These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15839720)

  • 1. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review.
    Rouland JF; Berdeaux G; Lafuma A
    Drugs Aging; 2005; 22(4):315-21. PubMed ID: 15839720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic implications of glaucoma: a literature review.
    Schmier JK; Halpern MT; Jones ML
    Pharmacoeconomics; 2007; 25(4):287-308. PubMed ID: 17402803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An observational, retrospective two-year cost study in primary open-angle glaucoma and ocular hypertension in newly diagnosed patients].
    Rouland JF; Peigne G; Sellem E; Renard JP; Williamson W; Filippi JM; Cohn H; Hamard P; Abellan P; Chagnon A; Malet F; Haye I
    J Fr Ophtalmol; 2001 Mar; 24(3):233-43. PubMed ID: 11285438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.
    Lee PP; Walt JG; Doyle JJ; Kotak SV; Evans SJ; Budenz DL; Chen PP; Coleman AL; Feldman RM; Jampel HD; Katz LJ; Mills RP; Myers JS; Noecker RJ; Piltz-Seymour JR; Ritch RR; Schacknow PN; Serle JB; Trick GL
    Arch Ophthalmol; 2006 Jan; 124(1):12-9. PubMed ID: 16401779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches.
    Orme M; Collins S; Loftus J
    J Glaucoma; 2012 Sep; 21(7):433-49. PubMed ID: 21677590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands.
    Oostenbrink JB; Rutten-van Mölken MP; Sluyter-Opdenoordt TS
    J Glaucoma; 2001 Jun; 10(3):184-91. PubMed ID: 11442180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.
    Lindblom B; Nordmann JP; Sellem E; Chen E; Gold R; Polland W; Williamson W; Buchholz P; Walt JG; Groleau D; Curry A; Evans SJ
    Acta Ophthalmol Scand; 2006 Feb; 84(1):74-83. PubMed ID: 16445443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study.
    Kymes SM; Kass MA; Anderson DR; Miller JP; Gordon MO;
    Am J Ophthalmol; 2006 Jun; 141(6):997-1008. PubMed ID: 16765666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications.
    De Natale R; Draghi E; Dorigo MT
    Acta Ophthalmol Scand; 2004 Aug; 82(4):393-6. PubMed ID: 15291930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations in developing model-based economic evaluations of glaucoma treatment.
    Althin R; Grima DT; Dhawan R; Bernard LM
    J Glaucoma; 2006 Dec; 15(6):541-7. PubMed ID: 17106369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States.
    Kobelt-Nguyen G; Gerdtham UG; Alm A
    J Glaucoma; 1998 Apr; 7(2):95-104. PubMed ID: 9559495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.
    Rouland JF; Le Pen C; Benhaddi H; Piriou E; Lilliu H; Kenigsberg PA;
    Eur J Ophthalmol; 2005; 15(5):562-80. PubMed ID: 16167287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension.
    Fiscella R; Walt J
    Drugs Aging; 2006; 23(1):39-47. PubMed ID: 16492068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial.
    Lamoureux EL; Mcintosh R; Constantinou M; Fenwick EK; Xie J; Casson R; Finkelstein E; Goldberg I; Healey P; Thomas R; Ang GS; Pesudovs K; Crowston J
    Trials; 2015 Sep; 16():406. PubMed ID: 26362541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe.
    Traverso CE; Walt JG; Kelly SP; Hommer AH; Bron AM; Denis P; Nordmann JP; Renard JP; Bayer A; Grehn F; Pfeiffer N; Cedrone C; Gandolfi S; Orzalesi N; Nucci C; Rossetti L; Azuara-Blanco A; Bagnis A; Hitchings R; Salmon JF; Bricola G; Buchholz PM; Kotak SV; Katz LM; Siegartel LR; Doyle JJ
    Br J Ophthalmol; 2005 Oct; 89(10):1245-9. PubMed ID: 16170109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effective evaluation of the glaucoma suspect.
    Doshi A; Singh K
    Curr Opin Ophthalmol; 2007 Mar; 18(2):97-103. PubMed ID: 17301609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension.
    Cvetkovic RS; Perry CM
    Drugs Aging; 2003; 20(12):919-47. PubMed ID: 14565787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of ocular hypertension: is it cost effective?
    Tuulonen A
    Curr Opin Ophthalmol; 2016 Mar; 27(2):89-93. PubMed ID: 26569531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension.
    van Gestel A; Schouten JS; Beckers HJ; Severens JL; Hendrikse F; Webers CA
    Acta Ophthalmol; 2014 Sep; 92(6):513-23. PubMed ID: 24330516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension.
    Plosker GL; Keam SJ
    Pharmacoeconomics; 2006; 24(3):297-314. PubMed ID: 16519552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.